相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-1 Blockade in Advanced Adrenocortical Carcinoma
Nitya Raj et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Viktor Grunwald et al.
FUTURE ONCOLOGY (2019)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker et al.
LANCET ONCOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
Monica Capozzi et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Benedito A. Carneiro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
Lia Head et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2019)
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one
M. Nuti et al.
CANCER TREATMENT REVIEWS (2018)
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Takayuki Kimura et al.
CANCER SCIENCE (2018)
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
Christophe Le Tourneau et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Liem M. Phan et al.
CANCER RESEARCH (2015)
The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer
Ciara O'Sullivan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
The role of fibroblast growth factor receptor 4 overexpression and gene amplification as prognostic markers in pediatric and adult adrenocortical tumors
Luciana Pinto Brito et al.
ENDOCRINE-RELATED CANCER (2012)
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
Alfredo Berruti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
Matthias Kroiss et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells
Matthias Kroiss
Frontiers in Endocrinology (2011)
Limited Prognostic Value of the 2004 International Union Against Cancer Staging Classification for Adrenocortical Carcinomas
Martin Fassnacht et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
